NEW YORK (Reuters Health) – A population-based study from Scotland shows that fewer than one in every 100 patients with subclinical hyperthyroidism will progress to overt hyperthyroidism. In…
NEW YORK (Reuters Health) – Among low-risk patients undergoing elective percutaneous coronary intervention, 1-year outcomes are worse if their antiplatelet response to clopidogrel is low, an Italian team…
NEW YORK (Reuters Health) – In patients being treated for acute coronary syndromes (ACS), the loading dose of ticagrelor has a stronger inhibitory effect on platelets than does…
NEW YORK (Reuters Health) – Among women treated for endometrial hyperplasia, regression rates appear to be better with the levonorgestrel-releasing intrauterine system than with oral progestogen treatment, according…
NEW YORK (Reuters Health) – In terms of efficacy and safety, low-molecular weight heparin is better than unfractionated heparin in the treatment of patients presenting with cerebral venous…
NEW YORK (Reuters Health) – Patients with atrial fibrillation undergoing pulmonary vein isolation by radiofrequency catheter ablation are less likely to have immediate recurrence of AF if they’re…
NEW YORK (Reuters Health) – Results of a meta-analysis indicate that anticoagulation may not need to be interrupted in patients undergoing elective coronary angiography. However, the quality of…
NEW YORK (Reuters Health) – For patients with multiple myeloma who are not eligible for autologous stem-cell transplantation, a four-drug combination regimen is promising. Adding thalidomide to bortezomib-melphalan-prednisone,…
NEW YORK (Reuters Health) – The GLP-1 receptor agonist exenatide used to treat type 2 diabetes is associated with a lower risk of cardiovascular disease (CVD) events, compared…